MEGAN MCGOEY: Open Payments
NPI 1679933287 · HAMMOND, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,024 in 27 payments from 11 companies in 2025. Trend: 2023 $1,281 · 2024 $1,033 · 2025 $1,024
Food & beverage: $1,024
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 4 | $340 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $265 |
| Teva Pharmaceuticals USA, Inc. | 9 | $141 |
| ABBVIE INC. | 1 | $112 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $42 |
| Otsuka America Pharmaceutical, Inc. | 2 | $34 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $19 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $18 |
| Lundbeck LLC | 1 | $18 |
Products named: CAPLYTA, AIRSUPRA, AUSTEDO XR, VRAYLAR, FARXIGA, REXULTI, XIFAXAN, VOQUEZNA.
Industry payments across LA — which companies pay providers there.
